4//SEC Filing
LINNIK MATTHEW D 4
Accession 0001209191-04-027889
CIK 0000920465other
Filed
May 24, 8:00 PM ET
Accepted
May 25, 9:52 PM ET
Size
10.7 KB
Accession
0001209191-04-027889
Insider Transaction Report
Form 4
LINNIK MATTHEW D
CSO & Exec VP of Research
Transactions
- Other
Common Stock
2004-03-31$1.48/sh+1,025$1,516→ 3,815 total - Award
Stock Options (right to buy)
2004-05-21+122,000→ 122,000 totalExercise: $2.96Exp: 2014-05-21→ Common Stock (122,000 underlying)
Footnotes (2)
- [F1]Acquired pursuant to the Company?s Employee Stock Purchase Plan.
- [F2]50% of the options vest on the date that the Company receives approval to market its lead drug candidate for the treatment of lupus and 1/24 of the remaining options vest at the end of each month thereafter until all of the options are vested. Notwithstanding the foregoing, if marketing approval is not obtained between the grant date and the three year anniversary of the grant date, then 100% of the options will vest on the three year anniversary of the grant date.
Issuer
LA JOLLA PHARMACEUTICAL CO
CIK 0000920465
Entity typeother
Related Parties
1- filerCIK 0001237521
Filing Metadata
- Form type
- 4
- Filed
- May 24, 8:00 PM ET
- Accepted
- May 25, 9:52 PM ET
- Size
- 10.7 KB